New antibody drug aims to tackle kidney disease
NCT ID NCT06642909
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new drug, zuberitamab, in 135 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. Participants receive either zuberitamab (two doses two weeks apart) or the standard drug cyclosporine. The main goal is to see if zuberitamab reduces protein in urine better than cyclosporine after 76 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zuberitamab (a monoclonal antibody)
What this could lead to
If successful, this could offer a new treatment option for primary membranous nephropathy, potentially reducing protein in urine and preserving kidney function.
What could go wrong
This is an early Phase 2 trial with only 135 participants, so results may not apply to everyone. The drug may not work better than cyclosporine, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China